Yeast Infection Treatment

Feel Better Faster with MONISTAT®

MONISTAT® may be a better choice than Diflucan® (fluconazole), the leading prescription pill, because:

  • MONISTAT® relieves yeast infection symptoms 4 times faster
  • MONISTAT® cures more of the most common types of yeast infections1,2
  • MONISTAT® starts working right at the site of infection
  • Your health insurance company may now require that you use over-the-counter miconazole/MONISTAT® before a prescription pill

The Rx pill may not be right for you

Fluconazole has safety risks for some women:

  • Are you pregnant or trying to become pregnant? A 2016 study reported that even 1 fluconazole pill may increase miscarriage risk significantly.3 The FDA recommends discussing treatment options other than fluconazole with a healthcare professional4
    — MONISTAT® 7 meets CDC Treatment Guidelines for pregnant women5*
  • Do you have diabetes? For women who take certain diabetes medicines (sulfonylureas), fluconazole may increase the risk of serious hypoglycemic episodes.6,7 Also, women with diabetes are more likely to have yeast infection types that fluconazole does not treat8,9
    — MONISTAT® 7 is appropriate for many women with diabetes5 If you are diabetic, consult your healthcare professional before using any yeast infection drug.

MONISTAT® is available in 3 strengths, giving you the choice of a 1, 3, or 7-day treatment. Get a money-saving coupon.

*For vaginal yeast infections in pregnant women, 2015 CDC Treatment Guidelines recommend use of a 7-day topical azole therapy. If you are pregnant, consult your healthcare professional before using any yeast infection drug.

Diflucan is a registered trademark of Pfizer Inc.

  1. Highest Dose
    Monistat® 1

    This selection of single-dose products (1200 mg of miconazole nitrate) may be the perfect solution for busy women with active lifestyles. Use as directed. 

    See all products
  2. Regular Strength
    Monistat® 3

    MONISTAT® 3 is a great treatment option for women who want a less concentrated treatment (200 mg of miconazole nitrate per dose) that provides consistent treatment and relief at moderate dosage levels. Use as directed.

    See all products
  3. Low Dose
    Monistat® 7

    The MONISTAT® 7 suite of products is a low dose formula (100 mg of miconazole nitrate per dose), with smaller doses of the active ingredient evenly distributed throughout the week at bedtime. MONISTAT® 7 meets CDC Treatment Guidelines for pregnant women and is appropriate for women with diabetes. (Consult a healthcare professional before use.) Use as directed.

    See all products

References: 1. ISSVD. (2016). Vulvovaginal Candidiasis (Candida, Yeast): Tips for Diagnosis and Treatment (Version 1.0) [Mobile application software]. Retrieved from http://itunes.apple.com. 2. Richter SS, et al. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43(5):2155-2162. 3. Mølgaard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA. 2016;315(1):58-67. 4. Lowes R. Low-dose fluconazole in pregnancy worries FDA. Available at: http://www.medscape.com/viewarticle/862447. Published April 26, 2016. Accessed August 26, 2017. 5. Centers for Disease Control and Prevention. Vulvovaginal candidiasis. Available at: http://www.cdc.gov/std/tg2015/candidiasis.htm. Updated June 4, 2015. Accessed August 26, 2017. 6. May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69-83. 7. Diflucan [prescribing information]. New York, NY: Roerig; 2013. 8. Goswami D, Goswami R, Banerjee U, et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect. 2006;52(2):111-117. 9. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med. 2015;125(3):33-46.